Novartis Gets Accelerated FDA Approval for Dabrafenib/Trametinib
FDA granted accelerated approval to Novartis’s dabrafenib and trametinib combo for treating BRAF V600E mutation-positive unresectable or metastatic solid tumors in patients aged 6+ with no satisfactory alternatives. Novartis shares slightly dropped to CHF78.23, with a 12-month target of CHF90.75.
Reference News
Novartis Gets Accelerated FDA Approval for Dabrafenib/Trametinib
FDA granted accelerated approval to Novartis’s dabrafenib and trametinib combo for treating BRAF V600E mutation-positive unresectable or metastatic solid tumors in patients aged 6+ with no satisfactory alternatives. Novartis shares slightly dropped to CHF78.23, with a 12-month target of CHF90.75.